The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

Clin Infect Dis. 2015 Aug 15;61(4):496-502. doi: 10.1093/cid/civ334. Epub 2015 Apr 22.

Abstract

Background: The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.

Methods: We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma.

Results: While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date.

Conclusions: It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.

Keywords: Ebola virus; Ebola virus disease; TKM-Ebola; convalescent plasma; convalescent serum.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antibodies, Viral / therapeutic use*
  • Hemorrhagic Fever, Ebola / therapy*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • RNA, Small Interfering / therapeutic use*
  • Treatment Outcome
  • United States

Substances

  • Antibodies, Viral
  • RNA, Small Interfering